These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 2643594)

  • 1. Sequential hemibody radiotherapy in poor prognosis localized adenocarcinoma of the prostate gland: a preliminary study of the RTOG.
    MacLennan I; Selim HM; Rubin P
    Int J Radiat Oncol Biol Phys; 1989 Jan; 16(1):215-8. PubMed ID: 2643594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II.
    Michalski JM; Winter K; Purdy JA; Wilder RB; Perez CA; Roach M; Parliament MB; Pollack A; Markoe AM; Harms W; Sandler HM; Cox JD
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):192-8. PubMed ID: 12694838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 32P therapy and sequential hemibody irradiation (HBI) for bony metastases as methods of whole body irradiation.
    Aziz H; Choi K; Sohn C; Yaes R; Rotman M
    Am J Clin Oncol; 1986 Jun; 9(3):264-8. PubMed ID: 2425617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute non-lymphocytic leukaemia and myelofibrosis following sequential hemibody irradiation for prostatic carcinoma.
    Chin-Yee I; Porter AT; Lohmann RC
    Clin Oncol (R Coll Radiol); 1991 Sep; 3(5):288-90. PubMed ID: 1931775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
    Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
    Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years.
    Anscher MS; Clough R; Dodge R
    Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):369-75. PubMed ID: 10974449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate.
    Anscher MS; Samulski TV; Dodge R; Prosnitz LR; Dewhirst MW
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1059-65. PubMed ID: 9169813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy: preliminary results of RTOG 83-07.
    Pilepich MV; Krall JM; John MJ; Rubin P; Porter AT; Marcial VA; Martz KL
    Int J Radiat Oncol Biol Phys; 1989 Mar; 16(3):813-7. PubMed ID: 2646266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
    Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fast neutron radiotherapy for locally advanced prostate cancer: results of an RTOG randomized study.
    Laramore GE; Krall JM; Thomas FJ; Griffin TW; Maor MH; Hendrickson FR
    Int J Radiat Oncol Biol Phys; 1985 Sep; 11(9):1621-7. PubMed ID: 3897156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20).
    Lawton CA; Coleman CN; Buzydlowski JW; Forman JD; Marcial VA; DelRowe JD; Rotman M
    Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):673-80. PubMed ID: 8948352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.
    Zietman AL; DeSilvio ML; Slater JD; Rossi CJ; Miller DW; Adams JA; Shipley WU
    JAMA; 2005 Sep; 294(10):1233-9. PubMed ID: 16160131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report.
    Martinez AA; Pataki I; Edmundson G; Sebastian E; Brabbins D; Gustafson G
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):61-9. PubMed ID: 11163498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combination of external irradiation and androgen suppression for prostate cancer: facts and questions].
    Bolla M; Fourneret P; Beneyton V; Tessier A; Jover F; Verry C
    Cancer Radiother; 2010 Oct; 14(6-7):510-4. PubMed ID: 20728391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [External radiotherapy with curative intent for adenocarcinoma clinically localized to the prostate (T1 to T3N0M0): intermediate results with a minimum follow-up of 4 years].
    Rohner S; Bieri S; Graber P
    Ann Urol (Paris); 1994; 28(4):221-8. PubMed ID: 7979212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irradiation of carcinoma of the prostate localized to the pelvis: analysis of tumor response and prognosis.
    Perez CA; Walz BJ; Zivnuska FR; Pilepich M; Prasad K; Bauer W
    Int J Radiat Oncol Biol Phys; 1980 May; 6(5):555-63. PubMed ID: 7410129
    [No Abstract]   [Full Text] [Related]  

  • 18. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.
    Ryan CJ; Zelefsky MJ; Heller G; Regan K; Leibel SA; Scher HI; Kelly WK
    Urology; 2004 Jul; 64(1):90-4. PubMed ID: 15245942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group.
    Lawton CA; Winter K; Byhardt R; Sause WT; Hanks GE; Russell AH; Rotman M; Porter A; McGowan DG; DelRowe JD; Pilepich MV
    Int J Radiat Oncol Biol Phys; 1997 Jul; 38(5):931-9. PubMed ID: 9276357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.